Literature DB >> 22420808

Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010.

Heidi M Bauer1, Glenn Wright, Joan Chow.   

Abstract

Because of the rapid development of genital warts (GW) after infection, monitoring GW trends may provide early evidence of population-level human papillomavirus (HPV) vaccine effectiveness. Trends in GW diagnoses were assessed using public family planning administrative data. Between 2007 and 2010, among females younger than 21 years, these diagnoses decreased 35% from 0.94% to 0.61% (P(trend) < .001). Decreases were also observed among males younger than 21 years (19%); and among females and males ages 21-25 (10% and 11%, respectively). The diagnoses stabilized or increased among older age groups. HPV vaccine may be preventing GW among young people.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22420808      PMCID: PMC3483904          DOI: 10.2105/AJPH.2011.300465

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  14 in total

Review 1.  Post-licensure monitoring of HPV vaccine in the United States.

Authors:  Lauri E Markowitz; Susan Hariri; Elizabeth R Unger; Mona Saraiya; S Deblina Datta; Eileen F Dunne
Journal:  Vaccine       Date:  2010-02-25       Impact factor: 3.641

2.  Development of genital warts after incident detection of human papillomavirus infection in young men.

Authors:  Yuzo Arima; Rachel L Winer; Qinghua Feng; James P Hughes; Shu-Kuang Lee; Michael E Stern; Sandra F O'Reilly; Laura A Koutsky
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

3.  Adult vaccination coverage--United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-02-03       Impact factor: 17.586

4.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Herschel W Lawson; Harrell Chesson; Elizabeth R Unger
Journal:  MMWR Recomm Rep       Date:  2007-03-23

Review 5.  What can surveillance of genital warts tell us?

Authors:  Christopher K Fairley; Basil Donovan
Journal:  Sex Health       Date:  2010-09       Impact factor: 2.706

Review 6.  Evaluating the impact of human papillomavirus vaccines.

Authors:  Yuli Chang; Noel T Brewer; Allen C Rinas; Karla Schmitt; Jennifer S Smith
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

Review 7.  Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.

Authors:  Luisa Lina Villa
Journal:  Int J Infect Dis       Date:  2007-11       Impact factor: 3.623

8.  Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999--2004.

Authors:  Thu-Ha Dinh; Maya Sternberg; Eileen F Dunne; Lauri E Markowitz
Journal:  Sex Transm Dis       Date:  2008-04       Impact factor: 2.830

Review 9.  Quadrivalent human papillomavirus vaccine.

Authors:  Eliav Barr; Gretchen Tamms
Journal:  Clin Infect Dis       Date:  2007-07-25       Impact factor: 9.079

Review 10.  Epidemiology and natural history of human papillomavirus infections in the female genital tract.

Authors:  Kevin A Ault
Journal:  Infect Dis Obstet Gynecol       Date:  2006
View more
  30 in total

1.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

2.  Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States.

Authors:  Anthony E Yakely; Lital Avni-Singer; Carlos R Oliveira; Linda M Niccolai
Journal:  Sex Transm Dis       Date:  2019-04       Impact factor: 2.830

Review 3.  Addressing HPV vaccine myths: practical information for healthcare providers.

Authors:  Robert A Bednarczyk
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

4.  Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.

Authors:  Julia Warner Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Michelle L Johnson Jones; Erin Whitney; Manideepthi Pemmaraju; Monica Brackney; Nasreen Abdullah; Mary Scahill; Rebecca M Dahl; Angela A Cleveland; Elizabeth R Unger; Lauri E Markowitz
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

5.  Implementation Challenges and Opportunities Related to HPV Vaccination Quality Improvement in Primary Care Clinics in a Rural State.

Authors:  Natoshia M Askelson; Grace Ryan; Laura Seegmiller; Felicia Pieper; Bethany Kintigh; Donald Callaghan
Journal:  J Community Health       Date:  2019-08

6.  Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis.

Authors:  L R Avni-Singer; A Yakely; S S Sheth; E D Shapiro; L M Niccolai; C R Oliveira
Journal:  Public Health       Date:  2019-11-04       Impact factor: 2.427

7.  Prevalence of genital warts among sexually transmitted disease clinic patients-sexually transmitted disease surveillance network, United States, January 2010 to December 2011.

Authors:  Eloisa Llata; Mark Stenger; Kyle Bernstein; Sarah Guerry; Roxanne Kerani; River Pugsley; Preeti Pathela; Irina Tabidze; Hillard Weinstock
Journal:  Sex Transm Dis       Date:  2014-02       Impact factor: 2.830

Review 8.  EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection.

Authors:  Anna R Giuliano; Alan G Nyitray; Aimée R Kreimer; Christine M Pierce Campbell; Marc T Goodman; Staci L Sudenga; Joseph Monsonego; Silvia Franceschi
Journal:  Int J Cancer       Date:  2014-07-26       Impact factor: 7.396

9.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Prospects for prevention of HPV-driven oropharynx cancer.

Authors:  Aimée R Kreimer
Journal:  Oral Oncol       Date:  2013-07-19       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.